6-0-Methylerythromycin B has been synthesized from erythromycin B via regioselective methylation of the 6-hydroxyl group in 71 %overall yield. This compound shows in vitro antibacterial activity comparable to erythromycins A and B and exhibits superior in vivo activity with improved pharmacokinetic properties.
In the previous paper we have described the synthesis and the antibacterial activity of 0-alkyl derivatives of erythromycin A (1, EM-A)lf 2). Among them, 6-O-methylerythromycin A (2, clarithromycin, TE-031) showed more potent antibacterial activity than 1 and superior pharmacokinetic properties. Erythromycin B (3, EM-B, 12-deoxyerythromycin A), a biosynthetic precursor of 1, is produced as a minor product by H  H  OH  CH3  H  2  CH3  H  H  OH  CH3  H  3  H  H  H  H  CH3  H  4  CH3  H  H  H  CH3  H  5  H  H  CH3  H  CH3  H  6  CH3  CH3  H  H  CH3  H  7  CH3 CH3 CH3  H  CH3  H  8  H  H  H  H  Z  Z  9  CH3  H  H  H  Z  Z  10  H  H  CH3  H  Z  Z  ll  CH3  CH3  H  H  Z  Z  12  CH3 CH3 CH3  H  Z  Z  13  H  H  H Catalytic hydrogenation of 9, 10, ll and 12 using Pd-Black in EtOH containing 2.5 m acetate buffer (pH 5.0) and reductive JV-methylation with formaldehyde afforded 4 (93%), 1 1-O-methylerythromycin B (5, 61%), 6,4"-di-O-methylerythromycm B (6, 69%) and 6,l l,4"-tri-O-methylerythromycin B (7, 48%), respectively.
The molecular formula of 4 was determined as C38H69NO12from elemental analysis, FAB-MSand 13C NMRspectra, indicating the introduction of a methyl group to 3. The *H and 13C NMRspectra of 4 were directly compared with those of 3 ( Table 1 ). The *H NMRspectrum of 4 is similar to that of 3 except for the new O-methyl signal at 3.10ppm. In the 13C NMRspectrum, C-6 (78.7ppm) of4 is 3.6ppm further down field than that of3. Up field shifts ofC-5 (-2.9 ppm) and G-18 (-7.2 ppm) were also observed. The spectral data of 4 are consistent with the published substituent effect in 22). The structure of 4 is therefore determined to be 6-O-methylerythromycin B.
The molecular formulae of 6 and 7 were determined as C39H71NO12and C40H73NO12,respectively, from FAB-MS, 13C NMRspectra and elemental analyses, indicating the introduction of two and three methyl groups to 3, respectively. Compound6 exhibits the new O-methyl signal at 3.54ppm in addition to the 6-O-methyl signal at 3.10ppm. The *H NMRspectrum of 7 showed one more O-methyl signal at 3.44ppm besides two O-methyl signals at 3.54 and 3.16ppm which were similar to those observed in 6. In the 13C NMRspectrum of 6, a typical downfield shift of C-4" (+ ll.0ppm) was observed together with the new O-methyl signal at 62.1 ppm compared to 3. Compound 7 showed down field shifts of C-l l (+9.4ppm) and C-4" (+ ll.1 ppm) together with the O-methyl signals at 60.1 and 62.2ppm compared to 3 . The structures of 6 and 7 were therefore determined to be 6,4"-di-O-methyland 6,ll,4"-tri-0-methylerythromycins B, respectively. The molecular formula of 5 was determined as C38H69NO12from elemental analysis, FAB-MSand 13C NMRspectra, indicating the introduction of a methyl group to 3, which was the same as that of 4. In the *H NMRspectrum of 5, the O-methyl signal was newly observed at 3.28ppm. In the 13C NMR spectrum, the (9-methyl signal (59.9ppm) and C-l l (79.3 ppm) in 5 were similar to the 1 1-O-methyl signal (60.1ppm) and C-ll (78.7ppm) in 7, respectively. The structure of 5 was therefore determined to be 1 1 -O-methylerythromycin B.
Selectivity for methylation of EM-Bderivative 8 is considerably different from that of EM-Aderivative 13. Methylation of 13 with Mel/KOH in DMSO-l,2-dimethoxyethane afforded the ll-0-methylated compoundas the major product, some 6-O-methylated compound, and small amounts of 6,ll-and 6,12-di-(9-methylated compounds2). On the other hand, the 6-hydroxyl group in 8 is much more reactive than the ll-hydroxyl and the 4"-hydroxyl groups. Compound 8 is different from 13 only by the lack of the 1 2-hydroxyl group. The above significant difference for methylation is caused by the neighboring group effect of the 12-hydroxyl group. Weare studying the reason for the selectivities by theoretical calculation using molecular mechanics (MM2') and molecular orbital method (MNDO).
Biological Property Table 2 shows the in vitro antibacterial activities of 6-O-methylerythromycins B (4, 6 and 7) and ll-0-methylerythromycin B (5) compared to those of 1, 2 and 3 against a variety of standard strains. 6-0-Methylerythromycin B (4) is equal to or 2-fold more active than 3, and equal to or 2-fold less active than 2. ll-0-Methylerythromycin B (5) is equal to or 2-fold less active than 4. Di-and tri-0-methylerythromycins B (6 and 7) are much less active than 4. The in vivo activities of I, 2, 3 and 4 are listed in Table 3 . Compound4 is 2-fold more effective than 1 and 3, but less effective than 2 against experimental infections by Staphylococcus aureus Smith 4. The hydroxyl group at C-12 plays an important role for in vivo antibacterial activity. Pharmacokinetic properties of 1, 2, 3 and 4 were compared after oral administration to rats in Table   Table 2 . In vitro antibacterial activities.
MICs (ug/ml) Inoculum size: 106 cfu/ml.
Medium: Sensitivity Test Agar (Eiken). (1) has been one of the most useful macrolide antibiotics for the past three decades5'6). We have synthesized clarithromycin (2) , which is expected to supersede EM-Aas a new antibiotic. This compound exhibits excellent antibacterial activity and preferable pharmacokinetic properties, which were brought by 6-6>-methylation2).
6-0-Methylerythromycin B (4) was synthesized from EM-B (3) in 71 % overall yield. Methylation of the 6-hydroxyl group in 8 is considerably regioselective, which could not be presumed from methylation of EM-Aderivative (13). Methylation of the 6-hydroxyl group does not affect the in vitro antibacterial activity significantly, but improves the in vivo activity due to the preferable pharmacokinetic properties. 6-O-Methylerythromycin B (4) is expected to be a promising antibiotic as well as clarithromycin (2) . Experimental MP's are uncorrected. IR and UVspectra were recorded with a Perkin-Elmer 1 760 FT-IR spectrometer and a Shimadzu UY240 spectrophotometer, respectively. Optical rotations were measured on a Jasco DIP-360 digital polarimeter. NMRspectra were recorded with a Jeol JNM-GX400 spectrometer. Mass spectra were measured on a Jeol JMS-SX102spectrometer equipped with a Jeol JMA-DA6000 data system using FABtechniques.
2/-O, 3'-Ar-Bis(benzyloxycarbonyl)-Ar-demethylerythromycin B (8) To a vigorously stirred suspension of NaHCO3(270 g) in carbobenzoxy chloride (500g) was added 3 (135g) in small portions at 40~50°C for lhour. The mixture was stirred for 1.5hours at the same temperature, and CH2C12(350 ml) was added. The reaction mixture was filtered, and the solid was washed with CH2C12(500 ml). The filtrate was evaporated under reduced pressure. Crystallization of the residue from ethyl ether-petroleum ether (100ml/4.5liters) afforded 8 (161.8 g, 88%) as colorless needles, mp 2/-O,3/-A^-Bis(benzyloxycarbonyl)-iV-demethyl-6-O-methylerythromycin B (9) and 2'-0,3'-iV-Bis-(benzyloxycarbonyl)-A^-demethyll l -O-methylerythromycin B (10) To a stirred solution of 8 (24.3 g) and Mel (3.9ml, 2.5equiv) in DMSO-1,2-dimethoxyethane (1 : 1, 500ml) was added 85% KOHpowder (2.47g, 1.5equiv) at 0~5°C in one portion. After the reaction mixture was stirred for 2.5 hours, triethyl amine (10ml) was added. The above mixture was poured into 5% NaHCO3soln, and extracted with EtOAc. The organic layer was washed with satd NaCl soln, dried over MgSO4 and evaporated under reduced pressure. The crude product was chromatographed on a silica gel column using EtOAc-«-hexane (1 :2) to afford 9 (21.4g, 87%), 10 (1.6g, 6%) and ll (1.0g, 4% H 8.07, N 1.42. Found: C 64.07, H 8.12, N 1.33. -O^'-iV-Bis^enzyloxycarbonylj-Ar-demethyl^^^-di-O-methylerythromycin B (1 1 ) To a stirred solution of8 (0.80g) and Mel (0.8ml, 16 equiv) in DMF(6.4ml) was added 60% NaH dispersion (64mg, 2.0 equiv) at 0~5°C in one portion, and the reaction mixture was stirred for 1.5 hours. 6-O-Methylerythromycin B (4) To a solution of 9 (21.42g) in 2.5m acetate buffer (pH 5.0, 24ml) and EtOH (200ml) was added Pd-black (1 g) and the mixture was stirred under hydrogen atmosphere for 3 hours at room temperature. After the complete removal of the benzyloxycarbonyl groups, 37% formaldehyde soln (40 ml) was added and hydrogenation was continued for further 3 hours. The catalyst was filtered off, and ice water (1 liter) was added to the filtrate. The resulting mixture was adjusted to pH 10~10.5 with 2n NaOHsoln under stirring to give the crude crystals. The crystals, collected by filtration, were washed with 2% NaHCO3 soln and water and dried. Crystallization from CHC13-petroleum ether afforded 4 (14.84g, 93% The reaction mixture was filtered, and the filtrate was poured into NaHCO3soln and extracted with EtOAc. The organic layer was washed with satd NaCl soln, dried over MgSO4and evaporated to give the crude product. Column chromatography of the crude product on silica gel with CHC13-MeOH-cone NH4OH(20 : 1 : 0. 6,4"-Di-O-methylerythromycm B (6)
By the method described above, ll (600mg) was hydrogenated and TV-methylated. Column
